ImmuNext derisks immunomodulatory targets and develops compounds on the cutting edge of immunotherapy for autoimmune diseases and cancer. Novel immunomodulators have been partnered with Janssen, Roche, Sanofi, Eli Lilly and Curis. ImmuNext currently has clinical stage programs with CD40L and VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.


The ImmuNext team combines expert immunology, preclinical development and business development in a tight-knit, well-coordinated team.

Corporate Site

ImmuNext is embedded within the Dartmouth-Hitchcock Medical Center in Lebanon, NH, which affords excellent access to both upstream academic research and downstream translational medicine.


Lebanon, NH provides us with a great combination of intellectual stimulation from Dartmouth College and the beauty of rural New England.